Mirtastad (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases the release of norepinephrine, and by antagonizing postsynaptic 5‑HT2 and 5‑HT3 receptors. This dual action enhances overall serotonergic and noradrenergic neurotransmission, contributing to its antidepressant effect.

The appropriate dose of Mirtastad is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and tolerability. Dosage adjustments are made according to clinical judgment and patient needs.

Safety data for mirtazapine in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirtastad (mirtazapine) belongs to the NaSSA class, which differs from SSRIs and SNRIs by its combined α2‑adrenergic antagonism and 5‑HT2/3 blockade. This mechanism often results in pronounced sedation and appetite stimulation, making it useful for patients with insomnia or weight loss, whereas other antidepressants may have different side‑effect profiles.

Mirtastad should be stored below 25 °C in its original packaging, protected from moisture and direct sunlight. Keeping the product in a dry, temperature‑controlled environment helps maintain its stability and potency.

Mirtastad is taken orally, usually once daily in the evening due to its sedative effect. The tablet should be swallowed whole with water and not chewed or crushed, unless otherwise directed by a healthcare professional.

Serious risks include the potential for serotonin syndrome when combined with other serotonergic drugs, agranulocytosis or severe neutropenia, significant weight gain, and the emergence or worsening of suicidal thoughts, especially during the initial treatment period.

Mirtastad is contraindicated in patients with known hypersensitivity to mirtazapine or any of its excipients, and it should be avoided in individuals currently taking monoamine oxidase inhibitors. Caution is also advised for patients with severe hepatic impairment or those at high risk for suicidal behavior.